ImmunityBio Faces Securities Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy IBRX?
Source: PRnewswire
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading statements made by its Chief Scientific Officer regarding Anktiva's efficacy during a podcast, involving investors from January 19 to March 24, 2026, highlighting significant deficiencies in the company's information disclosure practices.
- FDA Warning Impact: The FDA issued a warning letter to ImmunityBio, indicating that its promotional materials contained false or misleading information, which led to a more than 21% drop in the company's stock price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to submit claims, reflecting a strong concern for corporate compliance and transparency.
- Public Health Risks: The FDA emphasized that ImmunityBio's promotional materials grossly misrepresent the benefits of Anktiva, potentially impacting patient health, indicating that the company must exercise greater caution in product promotion to avoid legal and reputational risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.760
Low
5.00
Averages
7.33
High
9.00
Current: 7.760
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Reports 168% Revenue Growth in Q1 2026
- Significant Revenue Growth: ImmunityBio reported net product revenue of approximately $44.2 million in Q1 2026, reflecting a remarkable 168% year-over-year increase, which not only highlights strong demand for ANKTIVA but also indicates successful expansion into new markets.
- Strong Cash Position: As of March 31, 2026, the company had $380.9 million in cash, cash equivalents, and marketable securities, representing a 56.7% increase from $242.8 million as of December 31, 2025, providing ample funding for future R&D and market expansion initiatives.
- Clinical Trial Progress: The pivotal BCG-naïve NMIBC trial is fully enrolled, with the Independent Data Monitoring Committee confirming no additional patients are needed, laying the groundwork for a supplemental BLA submission in 2026 and demonstrating steady advancement in clinical development.
- Market Access Expansion: ANKTIVA has received approvals in approximately 34 countries, including its first approval in Asia by Macau, and achieved commercial availability within two months of announcing partnerships in the MENA region, showcasing the company's rapid global market positioning and strategic execution capabilities.
See More
ImmunityBio's Anktiva Application Decision Approaches
- FDA Review Deadline Approaches: The FDA's standard 60-day review window for ImmunityBio's resubmitted supplemental biologics license application for Anktiva expires Thursday, with potential approval significantly enhancing market competitiveness in treating difficult-to-treat non-muscle invasive bladder cancer.
- Positive Financial Outlook: Wall Street anticipates ImmunityBio's Q1 revenue to reach $43.9 million, a 15% increase from the previous quarter, while projected EBITDA losses are expected to narrow to $58 million, reflecting the company's ongoing growth momentum since Anktiva's commercial launch.
- Key Data Presentation: Next week at the American Urological Association Annual Meeting, ImmunityBio plans to present new comparative data on Anktiva against rival therapies, which could further boost investor confidence and elevate stock prices.
- FDA Leadership Turmoil: Recent leadership changes within the FDA's biologics and cancer divisions have raised concerns, potentially impacting the approval process for Anktiva, while market expectations for a more flexible stance on accelerated approvals are increasing.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Efficacy Claims Controversy: Soon-Shiong claimed in a podcast that Anktiva could treat all cancers, while the FDA stated that these promotional materials mislead the public and fail to provide complete information regarding Anktiva's FDA-approved indications, posing potential public health risks.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and is encouraging witnesses to assist in the investigation, demonstrating a commitment to protecting investor rights and pursuing corporate transparency.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: Purchasers of ImmunityBio, Inc. securities between January 19 and March 24, 2026, have until May 26, 2026, to seek lead plaintiff status in a class action lawsuit alleging violations of the Securities Exchange Act of 1934, potentially exposing investors to significant losses.
- False Statement Allegations: The lawsuit claims that ImmunityBio made false and misleading statements regarding its lead biologics product Anktiva, asserting it could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, which may undermine investor confidence.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio's CEO, stating that promotional materials misbranded Anktiva, violating the Federal Food, Drug, and Cosmetic Act, leading to a 21% drop in stock price, directly impacting the company's financial health.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, demonstrating its significant strength and influence in securities class action lawsuits.
See More
ImmunityBio Reports Q1 Loss but Strong Anktiva Demand Persists
- Financial Performance: ImmunityBio reported a Q1 net loss of $632.8 million, significantly up from $129.6 million a year ago, although revenue of $44.2 million slightly exceeded consensus estimates of $43.9 million, indicating financial strain on the company.
- Growing Anktiva Demand: Despite the increased losses, CEO Richard Adcock emphasized that demand for Anktiva continues to grow, particularly among new prescribers and in maintenance settings, suggesting the company's competitive position remains strong in the market.
- FDA Application Progress: ImmunityBio's resubmitted supplemental biologics license application is under FDA review, with data from the Quilt 3.032 study showing that 58.2% of patients remained cancer-free after 12 months, potentially supporting the company's future market performance.
- Investor Sentiment: On Stocktwits, retail investor sentiment for IBRX is deemed 'bullish', with many users expressing confidence in Anktiva and ImmunityBio's future developments, reflecting an optimistic outlook on the company's potential.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics faces a class action lawsuit for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that overstated FDA approval prospects, potentially leading to significant negative impacts on the company's financial condition.
- Coty Performance Decline: Coty Inc. is under scrutiny in a class action lawsuit covering November 5, 2025, to February 4, 2026, with claims that its Consumer Beauty segment underperformed, increased marketing investments compressed margins, and slowing growth in the Prestige fragrance market rendered the company's positive statements misleading.
- Super Micro Sales Violations: Super Micro Computer is implicated in a class action lawsuit for the period from February 2, 2024, to March 19, 2026, alleging that a significant portion of its server sales to Chinese companies violated U.S. export control laws, with material weaknesses in compliance controls leading to misleading positive statements about the company's operations.
- ImmunityBio Capability Overstatement: ImmunityBio faces a class action lawsuit for the period from January 19, 2026, to March 24, 2026, alleging that executive Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading positive statements about the company's business and operations, which could undermine investor confidence.
See More
ImmunityBio Reports 168% Revenue Growth in Q1 2026
- Significant Revenue Growth: ImmunityBio reported net product revenue of approximately $44.2 million in Q1 2026, reflecting a remarkable 168% year-over-year increase, which not only highlights strong demand for ANKTIVA but also indicates successful expansion into new markets.
- Strong Cash Position: As of March 31, 2026, the company had $380.9 million in cash, cash equivalents, and marketable securities, representing a 56.7% increase from $242.8 million as of December 31, 2025, providing ample funding for future R&D and market expansion initiatives.
- Clinical Trial Progress: The pivotal BCG-naïve NMIBC trial is fully enrolled, with the Independent Data Monitoring Committee confirming no additional patients are needed, laying the groundwork for a supplemental BLA submission in 2026 and demonstrating steady advancement in clinical development.
- Market Access Expansion: ANKTIVA has received approvals in approximately 34 countries, including its first approval in Asia by Macau, and achieved commercial availability within two months of announcing partnerships in the MENA region, showcasing the company's rapid global market positioning and strategic execution capabilities.
See More
ImmunityBio's Anktiva Application Decision Approaches
- FDA Review Deadline Approaches: The FDA's standard 60-day review window for ImmunityBio's resubmitted supplemental biologics license application for Anktiva expires Thursday, with potential approval significantly enhancing market competitiveness in treating difficult-to-treat non-muscle invasive bladder cancer.
- Positive Financial Outlook: Wall Street anticipates ImmunityBio's Q1 revenue to reach $43.9 million, a 15% increase from the previous quarter, while projected EBITDA losses are expected to narrow to $58 million, reflecting the company's ongoing growth momentum since Anktiva's commercial launch.
- Key Data Presentation: Next week at the American Urological Association Annual Meeting, ImmunityBio plans to present new comparative data on Anktiva against rival therapies, which could further boost investor confidence and elevate stock prices.
- FDA Leadership Turmoil: Recent leadership changes within the FDA's biologics and cancer divisions have raised concerns, potentially impacting the approval process for Anktiva, while market expectations for a more flexible stance on accelerated approvals are increasing.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Efficacy Claims Controversy: Soon-Shiong claimed in a podcast that Anktiva could treat all cancers, while the FDA stated that these promotional materials mislead the public and fail to provide complete information regarding Anktiva's FDA-approved indications, posing potential public health risks.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and is encouraging witnesses to assist in the investigation, demonstrating a commitment to protecting investor rights and pursuing corporate transparency.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: Purchasers of ImmunityBio, Inc. securities between January 19 and March 24, 2026, have until May 26, 2026, to seek lead plaintiff status in a class action lawsuit alleging violations of the Securities Exchange Act of 1934, potentially exposing investors to significant losses.
- False Statement Allegations: The lawsuit claims that ImmunityBio made false and misleading statements regarding its lead biologics product Anktiva, asserting it could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, which may undermine investor confidence.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio's CEO, stating that promotional materials misbranded Anktiva, violating the Federal Food, Drug, and Cosmetic Act, leading to a 21% drop in stock price, directly impacting the company's financial health.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, demonstrating its significant strength and influence in securities class action lawsuits.
See More
ImmunityBio Reports Q1 Loss but Strong Anktiva Demand Persists
- Financial Performance: ImmunityBio reported a Q1 net loss of $632.8 million, significantly up from $129.6 million a year ago, although revenue of $44.2 million slightly exceeded consensus estimates of $43.9 million, indicating financial strain on the company.
- Growing Anktiva Demand: Despite the increased losses, CEO Richard Adcock emphasized that demand for Anktiva continues to grow, particularly among new prescribers and in maintenance settings, suggesting the company's competitive position remains strong in the market.
- FDA Application Progress: ImmunityBio's resubmitted supplemental biologics license application is under FDA review, with data from the Quilt 3.032 study showing that 58.2% of patients remained cancer-free after 12 months, potentially supporting the company's future market performance.
- Investor Sentiment: On Stocktwits, retail investor sentiment for IBRX is deemed 'bullish', with many users expressing confidence in Anktiva and ImmunityBio's future developments, reflecting an optimistic outlook on the company's potential.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics faces a class action lawsuit for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that overstated FDA approval prospects, potentially leading to significant negative impacts on the company's financial condition.
- Coty Performance Decline: Coty Inc. is under scrutiny in a class action lawsuit covering November 5, 2025, to February 4, 2026, with claims that its Consumer Beauty segment underperformed, increased marketing investments compressed margins, and slowing growth in the Prestige fragrance market rendered the company's positive statements misleading.
- Super Micro Sales Violations: Super Micro Computer is implicated in a class action lawsuit for the period from February 2, 2024, to March 19, 2026, alleging that a significant portion of its server sales to Chinese companies violated U.S. export control laws, with material weaknesses in compliance controls leading to misleading positive statements about the company's operations.
- ImmunityBio Capability Overstatement: ImmunityBio faces a class action lawsuit for the period from January 19, 2026, to March 24, 2026, alleging that executive Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading positive statements about the company's business and operations, which could undermine investor confidence.
See More
